The immunohistochemical expression of endocrine gland-derived-VEGF (EG-VEGF) as a prognostic marker in ovarian cancer

Romanian Journal of Morphology and Embryology

Volumn 53, Issue 3, 2012, Pages 479-483

  Bǎlu, Sevilla ^a   Pirtea, L ^a   Gaje, Puşa ^a   Cîmpean, Anca Maria ^a   Raica, Marius ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Angiogenesis; EG VEGF; Immunohistochemistry; Ovarian carcinoma; Prognosis

Indexed keywords

EID: 84867004263     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries, Angiogenesis, 2005, 8(2):169-182.
2. Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer, Mol Pathol, 2002, 55(6):348-359.
3. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition, J Clin Oncol, 2007, 25(20):2894-2901.
4. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer, Br J Cancer, 2009, 100(1):1-7.
5. Raica M, Cimpean AM. Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy, Pharmaceuticals, 2010, 3(3):572-599.
6. LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, Keller GA, Peale F, Gurney A, Hillan KJ, Ferrara N. Identification of an angiogenic mitogen selective for endocrine gland endothelium, Nature, 2001, 412(6850):877-884.
7. Lin R, LeCouter J, Kowalski J, Ferrara N. Characterization of endocrine gland-derived vascular endothelial growth factor signaling in adrenal cortex capillary endothelial cells, J Biol Chem, 2002, 277(10):8724-8729.
8. Raica M, Coculescu M, Cimpean AM, Ribatti D. Endocrine gland derived-VEGF is down-regulated in human pituitary adenoma, Anticancer Res, 2010, 30(10):3981-3986.
9. Zhang L, Yang N, Conejo-Garcia JR, Katsaros D, Mohamed-Hadley A, Fracchioli S, Schlienger K, Toll A, Levine B, Rubin SC, Coukos G. Expression of endocrine glandderived vascular endothelial growth factor in ovarian carcinoma, Clin Cancer Res, 2003, 9(1):264-272.
10. Goi T, Fujioka M, Satoh Y, Tabata S, Koneri K, Nagano H, Hirono Y, Katayama K, Hirose K, Yamaguchi A. Angiogenesis and tumor proliferation/metastasis of human colorectal cancer cell line SW620 transfected with endocrine glands-derived-vascular endothelial growth factor, as a new angiogenic factor, Cancer Res, 2004, 64(6):1906-1910.
11. Morales A, Vilchis F, Chávez B, Chan C, Robles-Díaz G, Díaz-Sánchez V. Expression and localization of endocrine gland-derived vascular endothelial growth factor (EG-VEGF) in human pancreas and pancreatic adenocarcinoma, J Steroid Biochem Mol Biol, 2007, 107(1-2):37-41.
12. Ferrara N, Frantz G, LeCouter J, Dillard-Telm L, Pham T, Draksharapu A, Giordano T, Peale F. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries, Am J Pathol, 2003, 162(6):1881-1893.
13. Tavassoli FA, Devilee P. Tumours of the breast and female genital organs, WHO Classification of Tumors, IARC Press, Lyon, 2003, 117-145.
14. Monnier J, Samson M. Cytokine properties of prokineticins, FEBS J, 2008, 275(16):4014-4021.
15. Pasquali D, Rossi V, Staibano S, De Rosa G, ChieffiP, Prezioso D, Mirone V, Mascolo M, Tramontano D, Bellastella A, Sinisi AA. The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: up-regulation of EG-VEGF/prokineticin 1 with malignancy, Endocrinology, 2006, 147(9):4245-4251.
16. LeCouter J, Lin R, Ferrara N, The role of EG-VEGF in the regulation of angiogenesis in endocrine glands. In: LeCouter J. The cardiovascular system, Cold Spring Harbor Laboratory Press, 2002, LXVII:217-222.
17. Monnier J, Samson M. Prokineticins in angiogenesis and cancer, Cancer Lett, 2010, 296(2):144-149.
18. Ren LN, Li QF, Xiao FJ, Yan J, Yang YF, Wang LS, Guo XZ, Wang H. Endocrine glands-derived vascular endothelial growth factor protects pancreatic cancer cells from apoptosis via upregulation of the myeloid cell leukemia-1 protein, Biochem Biophys Res Commun, 2009, 386(1):35-39.
19. Lecouter J, Lin R, Ferrara N. EG-VEGF: a novel mediator of endocrine-specific angiogenesis, endothelial phenotype, and function, Ann N Y Acad Sci, 2004, 1014:50-57.
20. Fraser HM, Bell J, Wilson H, Taylor PD, Morgan K, Anderson RA, Duncan WC. Localization and quantification of cyclic changes in the expression of endocrine gland vascular endothelial growth factor in the human corpus luteum, J Clin Endocrinol Metab, 2005, 90(1):427-434.
21. Nagano H, Goi T, Koneri K, Hirono Y, Katayama K, Yamaguchi A. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer, J Surg Oncol, 2007, 96(7):605-610.
22. Jiang X, Abiatari I, Kong B, Erkan M, De Oliveira T, Giese NA, Michalski CW, Friess H, Kleeff J. Pancreatic islet and stellate cells are the main sources of endocrine glandderived vascular endothelial growth factor/prokineticin-1 in pancreatic cancer, Pancreatology, 2009, 9(1-2):165-172.
23. Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T, Mekada E. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy, Cancer Sci, 2006, 97(5):341-347.